Welcome to our dedicated page for Ifabric news (Ticker: IFABF), a resource for investors and traders seeking the latest updates and insights on Ifabric stock.
iFabric Corp. (OTCQX: IFABF, TSX: IFA) is active in performance apparel, advanced textiles, and fabric treatments, and its news flow reflects this focus. Through subsidiaries Intelligent Fabric Technologies (North America) Inc. (IFTNA) and Coconut Grove Pads Inc., the company announces developments in antimicrobial technologies, durable water repellents, intimate apparel, and performance-driven finished products.
News updates for iFabric often highlight technology deployments and brand partnerships. Recent releases describe license agreements and product launches involving Doctor’s Choice scrubs and medical apparel, Roots branded footwear at a Canadian wholesale club retailer, Verzus All Apparel programs, TUMI travel products featuring PROTX2, Marks & Spencer’s Autograph collections in the UK and EU, and functional bedding in collaboration with The Lad Collective.
Investors and observers can use the IFABF news stream to follow clinical validation milestones, such as the publication of a clinical trial in the Journal of Hospital Infection demonstrating statistically significant reductions in bacterial loads on PROTX2 and ecoPEL treated scrubs. Other updates cover financing and capital resources, including trade finance facilities intended to support growth and manage foreign exchange risk, as described by the company.
Coverage also includes new product category expansions for IFTNA’s technology platforms, such as moves into footwear and bedding, as well as the rollout of performance apparel brands through major retailers. For a concise view of how iFabric’s textile technologies are being adopted across apparel, healthcare, travel, and home categories, the IFABF news page aggregates these announcements in one place.
iFabric (OTCQX:IFABF) announced on January 13, 2026 that its subsidiary Intelligent Fabric Technologies (North America) will license patented bedding innovations from The Lad Collective to manufacture, market and distribute functional bedding across North America.
The agreement pairs TLC's utility-led, patent-protected designs (sold to >200,000 customers in Australia) with IFTNA's textile technologies, including PROTX2, aiming to introduce higher-function bedding to a market the company describes as lacking innovation.
iFabric (OTCQX:IFABF / TSX:IFA) announced that its subsidiary Intelligent Fabric Technologies (North America) launched a Roots branded footwear program with an initial nationwide rollout at a Canadian wholesale club retailer on January 7, 2026. The assortment was designed, developed, and produced by IFTNA and incorporates proprietary performance technologies for comfort, wearability, and freshness.
Based on partner commitments, IFTNA expects the initial launch to contribute approximately $8 million in incremental revenue in its first calendar year, with potential expansion into additional styles, seasonal offerings, and channels. The company positioned the program as part of broader 2026 product-category expansion following recent retail deployments including Walmart U.S. and Marks & Spencer in the UK/EU.
iFabric (OTCQX:IFABF) reported record Q3 2025 revenue of $9,021,607, up 111% YoY, driven by Intelligent Fabric division growth and new customer programs. Q3 adjusted EBITDA was $850,090 versus an adjusted loss in Q3 2024, and net earnings attributable to shareholders were $543,802 ($0.018/share). Management cited temporary margin pressure from U.S. tariffs and upfront ERP implementation costs; cash was $1,233,908 at quarter end.
YTD revenue was $21.90M (+30% YoY); Intelligent Fabrics YTD was $16.02M (+49%), while Intimate Apparel YTD declined 4% to $5.87M.
iFabric (OTCQX:IFABF / TSX:IFA) announced on November 3, 2025 that its subsidiary Intelligent Fabric Technologies (North America) is launching its company‑owned apparel brand Verzus All Apparel at one of Canada’s leading wholesale club retailers.
The retailer introduced five men's Verzus All Apparel programs initially available online, featuring performance apparel using IFTNA’s textile technologies. The retailer has planned an expanded rollout for Spring 2026, indicating confidence in the brand’s market potential. Verzus All programs emphasize enhanced comfort, durability, and protection to showcase IFTNA’s proprietary technologies to a broader consumer market.
An example selection is accessible via the retailer’s online search for Verzus.
iFabric Corp (OTCQX:IFABF, TSX:IFA) announced on October 27, 2025 that it secured a new $2.5 million unsecured trade finance facility with Ebury Partners Canada Ltd. The facility is intended to provide additional working capital and support growth and expansion initiatives.
The company said it will also use Ebury's foreign exchange expertise and flexible risk management tools to better manage currency exposure. This unsecured facility will supplement iFabric's existing secured credit facility of up to $12.0 million with a Canadian chartered bank, which management expects will together support anticipated new revenues from recently announced programs.
iFabric (OTCQX:IFABF) announced that its subsidiary Intelligent Fabric Technologies (North America) Inc. has begun the launch of Doctor's Choice Next Generation scrubs with an initial rollout at a leading U.S. national big-box retailer. The first collections integrate IFTNA flagship technologies: PROTX2 (advanced antimicrobial), ecoPEL (C0 PFC-free DWR), and DryTX (moisture management).
Collections will launch online first, with in-store availability expected at the end of October 2025. Product claims include clinically proven antimicrobial finish, PFC-free water repellency, and wicking/quick-dry performance designed for clinical use.
iFabric Corp (OTCQX:IFABF) has announced that its subsidiary, Intelligent Fabric Technologies North America (IFTNA), has signed a significant licensing agreement with Mercury Athletics LLC to develop next-generation medical apparel under the Doctor's Choice® brand.
The collaboration will incorporate IFTNA's textile technologies, particularly PROTX2®, into healthcare scrubs and apparel. The partnership builds on Doctor's Choice's established reputation in diabetic and compression socks, expanding into the healthcare apparel sector. The new product line will be supported by IFTNA's peer-reviewed clinical trial published in the Journal of Hospital Infection in 2025.
iFabric Corp (OTCQX:IFABF) has renewed its license agreement with TUMI through its subsidiary Intelligent Fabric Technologies North America (IFTNA). The five-year extension continues the integration of IFTNA's PROTX2® antimicrobial technology across select TUMI products.
The renewed partnership will maintain PROTX2 implementation in TUMI's premium product lines, including the 19 Degree Polycarbonate carry-on linings, Travel Kits, Toiletry Kits, Laundry Bags, and select items within the Alpha Bravo, Alpha, Arrive' and McLaren collections.
iFabric Corp (OTCQX:IFABF) announced the expansion of its PROTX2 technology into the United Kingdom and European Union markets, marking a significant strategic expansion beyond North America. The company has secured a notable partnership with Marks & Spencer, which will incorporate PROTX2 technology into select items within its Autograph collections.
The PROTX2 brand mark will be prominently featured on merchandise hang tags both in-store and online, increasing brand visibility in these new regional markets. The company's Intelligent Fabric Technologies Division will support production programs incorporating PROTX2 technology in both the EU and UK regions.
iFabric Corp (OTCQX:IFABF) has announced the publication of groundbreaking clinical trial results in the Journal of Hospital Infection, demonstrating the effectiveness of their PROTX2® and ecoPEL™ antimicrobial technologies in healthcare settings.
The trial, conducted at MemorialCare Saddleback Medical Center, is the first successful antimicrobial textile trial to show statistically significant bacterial load reductions on scrubs in a real-world healthcare environment. The study validates that scrubs treated with PROTX2® and PROTX2® combined with ecoPEL™ significantly reduce surface bacterial contamination compared to untreated scrubs.
PROTX2® is EPA-registered and available for use throughout the United States, positioning IFTNA as a leader in healthcare-associated infection prevention solutions.
FAQ
What is the current stock price of Ifabric (IFABF)?
What is the market cap of Ifabric (IFABF)?
